Whether Skyrizi will be able to address the patients’ unmet needs for patients with palmoplantar pustulosis with its ease in administration is receiving attention. As a maintenance therapy, Skyrizi can be administered every 12 weeks, making it easier to dose than other treatments. Doctors have analyzed that the use of such new biological agents would be highly useful for patients with palmoplantar pustulosis, as existing treatments had little effect until now.

On April 22, AbbVie Korea held a press conference at Andaz Hotel in Apgujeong, Seoul, to celebrate the approval of Skyrizi, a psoriatic disease treatment, for palmoplantar pustulosis.

Skyrizi is a biologic agent dev